type 2 diabetes

This indicates a shift from the conventional IR to the GLP1R as the primary target for pioneering T2D treatments

Zita DM helps improve glycemic control in adult patients with high HbA1c and/or other co-morbidities, those patients whose…

Liraglutide is a drug-device combination for the treatment and management of Type 2 diabetes and obesity

HTIT has recently submitted a marketing authorisation application in China for first oral insulin for type 2 diabetes

It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…

MKP10241 is a potent and orally administered small molecule, GPR119 agonist.

The FDC will be marketed under two brand names, Remo V and Remozen V, priced at Rs 14 per tab and Rs 28 per day cost of therapy

T2D market growth factors are increasing diagnosed prevalence of disease and the emergence of novel pipeline agents

The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11 trial

Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart…